Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06830863 | A Study to Evaluate Topical ATR04-484 for EGFRi-Associated Dermal Toxicity | PHASE1 | RECRUITING | 32 | — | — | Aug 25, 2025 | Feb 15, 2027 | Feb 11, 2026 | 6 | United States |
Treatment-emergent adverse events
| Arm | Type | Description |
|---|---|---|
| ATR04-484 | EXPERIMENTAL | Topically applied ATR04-484 |
| Vehicle | PLACEBO_COMPARATOR | Topically applied vehicle |
| Name | Type | Description |
|---|---|---|
| ATR04-484 | DRUG | ATR04-484 is a recombinant live biotherapeutic product (rLBP) containing the engineered S. epidermidis strain SE484 in an ointment formulation for topical use |
| Vehicle | DRUG | Topically applied vehicle. |
Inclusion Criteria: * Adults ≥18 years of age * Has Grade 2 or 3 non-infected moderate to severe EGFRi-related dermal toxicity affecting the face (the neck, chest, back and other areas may also be affected) Exclusion Criteria: * Significant skin disease other than EGFRi-related dermal toxicity * ...